MD Anderson Cancer Center and Allogene Therapeutics Inc. have entered into a five-year collaboration agreement for the preclinical and clinical investigation of AlloCAR T candidates across Allogene’s portfolio of hematologic and solid tumors.
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
